Enveric Biosciences, Inc.
ENVB
$1.46
$0.042.47%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -85.35% | 25.55% | -17.11% | 25.62% | -15.30% |
| Total Depreciation and Amortization | -1.08% | -5.82% | -2.23% | 1.00% | -50.62% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 15.51% | -59.84% | 362.61% | -71.74% | 7.84% |
| Change in Net Operating Assets | 154.79% | -868.13% | 133.37% | -178.37% | 179.93% |
| Cash from Operations | -8.32% | -26.44% | 13.98% | -9.78% | 20.97% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 134.25% | -6.91% | -10.14% | 566.31% | -89.91% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 133.50% | -6.91% | -10.14% | 566.31% | -89.91% |
| Foreign Exchange rate Adjustments | 14.57% | -196.79% | 262.50% | -166.67% | 7.69% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,364.55% | -74.86% | 1.33% | 162.84% | -170.35% |